Prospective study of high dose MTX with R-CHOP therapy for primary central nervous system lymphoma.

Prospective study of high dose MTX with R-CHOP therapy for primary central nervous system lymphoma. - MR-CHOP therapy for PCNSL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001343

Enrollment

Registered

2008-09-01

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary CNS lymphoma (CD20+ diffuse large B-cell lymphoma)

Interventions

6 courses of MR-CHOP therapy: high dose MTX (2g/m2) with standard dose R-CHOP. HDC/AHST if possible.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, PCNSL 2, primary case 3, Informed consent

Exclusion criteria

Exclusion criteria: 1, extra-CNS lesion 2, severe infectious disease 3, pre-treatment history for lymphoma 4, HIV+, HTLV1+, HBs-Ag+ 5, physician's decision of inappropriateness

Design outcomes

Primary

Measure	Time frame
Overall survival, CR rate	—

Secondary

Measure	Time frame
Adverse events	—

Countries

Japan

Contacts

Public ContactYasufumi Masaki

Kanazawa Medical University Hematology and Immunology

yasum@kanazawa-med.ac.jp076-286-3511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026